Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise

Aug 08 2022

• By Jessica Merrill

Sickle Cell Disease — Pfizer is expanding in the sickle cell disease space with GBT acquisition • Source: Shutterstock

Related Content

FDA Approval For Novartis’s Sickle Cell Treatment Adakveo

Nov 18 2019

Global Blood Therapeutics' Oxbryta Approved Broadly For Sickle Cell Disease

Nov 26 2019

GBT Picks Up Inclacumab From Roche's Bargain Bin

Aug 24 2018

GBT Bucks Gene Therapy Trend With Sanofi Sickle Cell Deal

Mar 17 2021

Pfizer Ends Pact With GlycoMimetics After SCD Failure

Feb 12 2020

Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase

May 10 2022

Sickle Cell Disease Market Snapshot: "The Time Has Come"

Oct 31 2019

Related Companies

Pfizer Inc.

GlycoMimetics, Inc.

Novartis AG

Roche Holding AG

Biohaven Pharmaceutical Holding Company Ltd.

ReViral Ltd.

Arena Pharmaceuticals, Inc.

Additional Topics

Deals M & A Rare Diseases Business Strategies Blood & Coagulation Disorders BioPharmaceutical

More from Blood and Clotting

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window